Investigation Commenced into Fairness of Revance Therapeutics Acquisition by Crown Laboratories
New York, NY – January 29, 2025
Levi & Korsinsky, LLP announces that it has commenced an investigation into the fairness of the acquisition of Revance Therapeutics Inc (“RVNC” or the “Company”) by Crown Laboratories, Inc. (“Crown”).
Background
On August 11, 2024, Revance Therapeutics and Crown Laboratories announced that they had entered into a definitive agreement under which Crown would acquire Revance for $2.1 billion. The transaction was approved by the Boards of Directors of both companies and is expected to close in the fourth quarter of 2024, subject to customary closing conditions.
The Investigation
The investigation concerns whether the acquisition price adequately reflects the value of the Company, taking into account the potential future performance of the business and the factors that may affect its value in the future. If you are a shareholder of Revance Therapeutics Inc (RVNC) and purchased your shares before August 11, 2024, you may be entitled to participate in this investigation.
Effects on Shareholders
If the investigation reveals that the acquisition price was unfair to Revance shareholders, they may be able to recover damages. The investigation may also lead to a negotiated resolution with Crown, including a potential increase in the acquisition price.
Effects on the World
The outcome of this investigation could have significant implications for the biotech industry and mergers and acquisitions more broadly. If it is determined that the acquisition price was unfair to Revance shareholders, it could deter similar transactions in the future, as companies may be less willing to pay premium prices for targets with strong growth prospects.
Conclusion
Levi & Korsinsky is dedicated to ensuring that institutions and individuals receive the maximum recovery available. If you wish to discuss this investigation or have any questions concerning this notice or your rights or interests, please contact Levi & Korsinsky, LLP conjointly by email at
- Revance Therapeutics Inc (RVNC)
- Crown Laboratories, Inc.
- Acquisition
- Investigation
- Fairness
- Shareholders
